HPV Treatment
Vaccination might be a useful part of treatment, to reduce recurrences:
While there are already non-HPV-specific therapies for cervical
cancer, researchers are looking for more effective HPV-specifc
therapies.
Perspectives for therapeutic HPV vaccine development has an overview
of therapeutic vaccines being tested as of 2016.
Older info:
So far, there are scattered reports of remission in
Phase II trials, but no Phase III trials have been carried out as
of 2011.
One frequently mentioned avenue is the use of
protease inhibitors.
Here are some specific vaccines that have been tested:
- Pentarix: A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors (
pubmed 21816200
)
- TG4001: Regression of high-grade cervical intraepithelial neoplasia
with TG4001 targeted immunotherapy. (
pubmed 21284968
)
- TA-CIN, a vaccine incorporating a recombinant HPV fusion
protein (HPV16 L2E6E7) for the potential treatment of HPV16-associated
genital diseases. (
pubmed 20886392 )
- SGN-00101: A phase II study of Hsp-7 (SGN-00101)
in women with high-grade cervical intraepithelial neoplasia. (
pubmed 17631950
)
- MVA E2: Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is
stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. (
pubmed 16456551
); MVA E2 recombinant vaccine in the treatment of human papillomavirus
infection in men presenting intraurethral flat condyloma: a phase I/II
study. (
pubmed 17263589 )
- TA-GW: Phase IIa safety and immunogenicity of a therapeutic vaccine,
TA-GW, in persons with genital warts. (
pubmed 9952367
)
- TA-HPV: A recombinant vaccinia virus encoding human papillomavirus
types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. (
pubmed 8684105 )
-- tested in 1996
You can
search clinicaltrials.gov for open therapeutic HPV clinical trials.
Here are a few such trials:
Here are some papers on the subject:
- Unique potential
of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when
combined with an E6/E7 peptide vaccine (pubmed 26351680)
- Targeting HPV16 E6-p300 interaction reactivates p53 and inhibits the tumorigenicity of HPV-positive head and neck squamous cell carcinoma. (
pubmed 23474763
)
- New Approaches to Immunotherapy for HPV Associated Cancers (
text
)
- Papillomavirus virus like particle-based therapeutic vaccine against human papillomavirus infection related diseases: immunological problems and future directions. (
pubmed 21477796
)
- HPV and Therapeutic Vaccines: Where are We in 2010? (
text
)
- Human papillomavirus-specific immune therapy: failure and hope (
text /
pubmed 21041909
)
- Immunotherapy for cervical cancer: Research status and clinical
potential (
pubmed 20199126 )
-
Highly potent and specific siRNAs against E6 or E7 genes of HPV16- or HPV18-infected cervical cancers (
text /
pubmed 20885450
)
-
Human immunodeficiency virus and human papilloma virus - why HPV-induced lesions do not spontaneously resolve and why therapeutic vaccination can be successful (
text /
pubmed 20021658
)
- Search for HPV treatment vaccine heats up, researchers optimistic (
pubmed 16849674
)
-
Vaccines against human papillomavirus and cervical cancer: promises and challenges. (
text
pubmed 16079320
)
Copyright 2011, 2012, 2013, 2014, 2015, 2016, 2019 Dan Kegel
Back to hpv.kegel.com